A detailed history of Citigroup Inc transactions in Infla Rx N.V. stock. As of the latest transaction made, Citigroup Inc holds 1,301 shares of IFRX stock, worth $2,914. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,301
Previous 1,301 -0.0%
Holding current value
$2,914
Previous $2,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$1.18 - $1.74 $1.42 Million - $2.09 Million
-1,200,000 Reduced 99.89%
1,301 $2,000
Q4 2023

Feb 09, 2024

BUY
$1.25 - $2.75 $1.5 Million - $3.3 Million
1,200,000 Added 92236.74%
1,201,301 $1.96 Million
Q3 2022

Nov 10, 2022

SELL
$1.32 - $3.14 $237 - $565
-180 Reduced 12.15%
1,301 $3,000
Q2 2022

Aug 10, 2022

SELL
$0.78 - $1.9 $4,152 - $10,115
-5,324 Reduced 78.24%
1,481 $2,000
Q1 2022

May 12, 2022

BUY
$1.83 - $4.48 $12,453 - $30,486
6,805 New
6,805 $13,000

Others Institutions Holding IFRX

About InflaRx N.V.


  • Ticker IFRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,203,800
  • Market Cap $99M
  • Description
  • InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...
More about IFRX
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.